AstraZeneca recently announced an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth global strategic R&D center, together with major research and manufacturing agreements. The new R&D center in Beijing will be AstraZeneca's second such center in China, following the opening of the first R&D center in Shanghai. In an exclusive interview with CGTN's Tian Wei on the sidelines of the Boao Forum for Asia Annual Conference 2025, AstraZeneca's CEO Pascal Soriot highlighted China's explosive growth in pharmaceutical innovation, making Beijing the company's next major R&D hub. Meanwhile, the team in Shanghai is the leader in global clinical programs, taking China's medical expertise to the world.